Statistical Model for HVD Canada Regulatory [RSABE / ABEL]

posted by pash413 – India, 2016-04-04 18:01 (2915 d 14:13 ago) – Posting: # 16164
Views: 5,134

Dear All

For HVD drugs recently Canada regulatory has published a notice proposing to adopt an average bioequivalence approach to HVDP with expanding limits based on the within-subject variability of the reference product.

As per general guidance of Canada mixed model is recommended for conventional two way crossover design.

Please suggest Which Statistical model to be followed for highly variable drugs (Canada Regulatory)?

I recommends widening of CI approach as recommended by EU, but do the Statistical analysis needs to be done same way i.e calculate Reference variability with separate model with only reference data and then analyse data with GLM and also check for outliers for Reference variability?

Or we can calculate reference variability as well as 90% CI with Mixed model (As per FDA for replicate study) and widen the acceptance limits as per reference variability, if necessary? :confused:


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
107 visitors (1 registered, 106 guests [including 10 identified bots]).
Forum time: 07:15 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5